This week's news includes a new cardio company, COO changes at DexCom and InfuSystem Holdings, and a round of financing for Halt Medical.
Mergers and Acquisitions
A new business, CardioLogical Solutions
(Los Altos, CA), has emerged from the merger of Emboline
(Freemont, CA)and VasoStitch
(Danville, CA). Emboline and VasoStitch both developed products to enable transcatheter procedures. former VasoStitch president and CEO David W.J. Smith will serve as CEO of CardioLogical Solutions. The company is in the midst of raising a Series B preferred financing round. Press Release
Thomas Medical (Indianapolis), a maker of disposable medical devices for female reproductive health, has acquired specific assets of medical products distributor Marshall Medical Systems & Equipment (Riverside, IL). Press Release
Natus Medical Inc.
(San Carlos, CA) will acquire Astro-Med Inc.
's (West Warwick, RI) Grass Technologies Product Group for $18.6 million in cash. The Grass Technologies Product Group includes neurodiagnostic and monitoring products including polysomnography and EEG systems. Natus specializes in products for screening, detection, treatment, and monitoring of newborns, hearing impariment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Press Release
Knee-brace maker DJO Global
(Vista, CA) has acquired Exos Corp.
(Arden Hills, MN), which produces thermoformable, waterproof braces and sheets, for an undisclosed sum. StarTribune
, former vice president of regulatory affairs and quality assurance for Guided Delivery Systems
(Santa Clara, CA), has joined BioVentrix
(San Ramon, CA) as vice president of regulatory and clinical affairs. BioVentrix recently received regulatory approval for its which recently Revivent Myocardial Anchroing System. Press Release
has been elevated to the position of chief operating officer at InfuSystem Holdings
(Madison Heights, MI). She had served as the infusion pump maker's vice president of operations and corporate compliance officer since 2007. Press Release
is the new chief operating officer at DexCom
(San Diego). He formerly served as the diabetes device maker's president. Press Release
(Brentwood, CA) has secured $15 million in financing to commercialize its Acessa System for treatment of Uterine Fibroids. The money will come from private equity firm American Capital Ltd. and current investors. Acessa was cleared by FDA in November 2013. San Francisco Business Times
Have news about a medtech move? E-mail us the details.
—Jamie Hartford is MD+DI's managing editor.